AMRI continues to up capacity amid ‘evolution of pharma pipelines’

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/lovelyday12)
(Image: iStock/lovelyday12)

Related tags: Pharmacology, Pharmaceutical drug

AMRI has more than doubled its bulk Active Pharmaceutical Ingredient (API) aseptic manufacturing capacity in response to an increasing need for sterile API and an evolving pharma pipeline, says CCO.

AMRI recently added a new multipurpose aseptic API line at its facility in Valladolid, Spain.

This new line – supported by a range of technologies – ensures aseptic processing of APIs with tailor-made specifications and control of the physical properties of the final product, including particle size distribution​,” George Svokos, chief commercial officer at AMRI told us.

The contract research, development, and manufacturing organization (CDMO) also recently announced the addition of an aseptic pre-filled syringe line at the company’s manufacturing facility in Albuquerque, NM, which Sovokos said adds the capacity to manufacture roughly 50m syringes per year.

There is growing interest by customers toward biologics, controlled substances, and other complex compounds, and our intent is to remain a key player for complex and sterile API development and manufacturing, as well as sterile dosage form development and manufacturing​,” he added.

As Svokos explained, there is "an evolution of pharma pipelines​" and an increasing need for sterile API.

"According to industry analysis, there are many parenteral products (existing and being approved) in the form of sterile suspensions and other such presentations – including certain inhaled or ophthalmic products – that require the use of sterile API in their manufacturing,​" he said, citing a Pharmaprojects Pharma R&D Annual Review. "This feeds well into our Drug Product business, which has capabilities in these types of sterile suspensions​." 

Over the past year, the Albany, NY-headquartered CDMO – which was acquired by a private equity firm in September​ – has invested more than $10m in its Spain facilities

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us


View more